Efficacy and Safety of Using Dual Versus Monotherapy Antiplatelet Agents in Secondary Stroke Prevention: Systematic Review and Meta-Analysis of Randomized Controlled Clinical Trials

This analysis (n=27,358) found dual antiplatelet therapy reduced risk of recurrent stroke (RR 0.71, 95% CI 0.63-0.81) and the composite of stroke, TIA, ACS and all-cause mortality (0.76, 0.69-0.83) but increased risk of major bleeding (2.17; 1.45-3.25).

Circulation